广济药业(000952.SZ)发布前三季度业绩，归母净亏损9730万元

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) reported a decline in revenue and significant losses in the third quarter of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved a revenue of 429 million yuan in the first three quarters, representing a year-on-year decrease of 7.12% [1] - The net profit attributable to the parent company was a loss of 97.3 million yuan [1] - The non-recurring net profit also showed a loss of 101 million yuan [1] - The basic earnings per share were reported at -0.2789 yuan [1]